Everyday FREE SHIPPINGFedEx Ground — Continental USwith a purchase of $75 or more
Build your own list of favorite items for easy reordering
In U.S. Call: 888-803-5333 International: 001.212.665.8070
Security Seals

BCN Office Hours: 9am to 5pm Monday Through Thursday

BCN Online Store Hours: 24/7 - That's every day, all day

My Account: Sign In

Be as specific as possibe for best search results

» BCN Formulas

» A.C. Grace UNIQUE E


» Boiron Homeopathics

» FoodScience of Vermont

» Freeda Vitamins

» Herbalist & Alchemist

» Hyalogic - True HA

» Jarrow Formulas

» MushroomScience

» Labrix Services

» Longevity Science

» Pure Body Institute

» Pharmax

» RX Vitamins

» Sonne's

» Your Energy Systems



» FAMILY Nutrition

» • Women's Nutrition

» • Children's Nutrition

» • Men's Nutrition

» • Senior Vitamins

» Anti-Aging

Bone and Joint

» Calcium Formulas

» CoQ10 / QH - Ubiquinol

» Cleansing

» Detox Nutrition & Herbs

» Digestive Health

» Energy

» Heart & Cardiovascular

» Herbal Products

» Immune Support


» Magnesium

» Mind, Memory & Mood

» Natural Hormones

» Omega 3 Fish Oils

» Phytosterols

» Probiotics

» Skin Care

» Urinary Tract Support

» Vision & Eye Health

» Vitamin D3

» Weight Management


» Your Personal Best

» Iron Supplements

» Pop-Up Specials

» Hold

» Kidney Support

» Internet Only Specials

Safe, Secure,
Online Ordering with:

Safe, Secure Ordering, By QuickSSL, 128-bit SSL certificate

Beachwood Canyon,
Naturally, Ltd.

Security Seals
Certified Seal
Privacy Seals
Business Seals

Advanced Bone Protection + Strontium- 60 vegi-caps - AOR (08181)
Advanced Bone Protection + Strontium- 60 vegi-caps -  AOR (08181) Quantity in Basket: None

Price: $0.00


*** Item Discontinued by Manufacturer ***
Advanced Bone Protection + Strontium® from AOR™ Advanced Orthomolecular Research
Please see product options below
Supports Skeletal Health*
Dosage: 361 mg
Size: 60 vegi-caps
Category: AOR
Product Number: 04181
See Below For:

Product Discussion
Background & Research
Supplement Facts
Article Abstracts
Frequently Asked Questions

Product Discussion: Advanced Bone Protection plus Strontium contains MBP, an active protein complex from the whey fraction of milk, and strontium, a trace mineral which concentrates in the skeletal system. Research suggests that MBP can positively impact bone health by reducing bone loss (resorption) and increasing bone mineral density. Strontium supports the function of osteoblasts (bone building cells) while reducing the differentiation and activity of osteoclasts (bone breakdown cells).

Advanced Bone Protection
Advanced Bone Protection contains Milk Basic Protein (MBP), a nutrient extracted from the whey fraction of milk. The terms ‘milk’ and ‘protein’ refer to the source and type of nutrient respectively, while the term ‘basic’ refers to its alkaline nature.

MBP greatly improves the absorption and retention of calcium within the bones, and it does so in a unique way. Part of MBP’s structure consists of a protein strain known as cystatin C, which inhibits an enzyme called cystein protease. Cystein protease releases calcium from bone and digests collagen in the bone matrix. MBP’s cystatin C blocks this enzyme, as well as other factors that contribute to calcium release from bone.

MBP also enhances the proliferation and activity of bone-building cells called osteoblasts, while at the same time preventing the proliferation and activity of bone-breaking cells (osteoclasts). MBP is capable of suppressing the activity of even the most isolated osteoclast. MBP’s ability to manipulate osteoblasts into producing more collagen is more pronounced than that of other nutrients for bone health.
MBP also increases serum concentrations of osteocalcin, which is the major non-collagenous protein in bone.

Studies with MBP:
• In a study among healthy menopausal women, the MBP group reported a bone mineral density (BMD) increase of 1.21% while the placebo group recorded a 0.66% BMD decrease.
• In another study among healthy adult women, the MBP group gained approximately 70% more bone mineral density than the control group.
• MBP reduced the number of pits on the bone surface caused by bone resorption by approximately 85% in an in-vitro study.
• In yet another study among healthy adult females, the MBP group displayed a 3% increase in the BMD of the radius (a forearm bone near the wrist) compared to a 1.3% BMD decrease in the placebo group.
• MBP was given to a group of normal healthy adult men, after 16 days their serum osteocalcin concentration had increased significantly, urinary markers of bone resorption had decreased significantly, suggesting that MBP promoted bone formation and suppressed bone resorption while maintaining the balance of bone remodeling.

Strontium is a mineral that is thought by many to be essential for the normal development, structure, function and health of the skeletal system. Unlike the existing drugs for osteoporosis treatment, as well as calcium and vitamin D, strontium does not work only by reducing bone resorption, but it actually increases the formation of new bone tissue. Furthermore, animal studies have shown that it boosts bone strength without a negative impact on bone quality, even at extremely high doses.

Strontium works by causing bone building osteoblasts to multiply more quickly, and cellular studies have shown that it causes bone tissue cultures to synthesize more bone matrix and new bone collagen.

One of the main ways strontium exerts its bone building effects is by activating the calcium-sensing receptor (CaR). CaRs are found throughout the body, including in the bones, the kidneys, the gastrointestinal system and several glands of the endocrine system, which are constituents of the body that are central to the regulation of calcium levels. These receptors are activated when calcium attaches to them. CaRs are found on the cells of the parathyroid gland, where parathyroid hormone (PTH) is secreted in response to low calcium levels and causes calcium to be released from bones. Strontium binds to CaRs to prevent the release of PTH.

CaR receptors are responsible for releasing calcitonin from the thyroid, a hormone which blocks the activity of osteoclasts and prevents urinary loss of calcium. CaRs are also found on osteoblasts, and when strontium attaches, they stimulate the proliferation of these bone building cells, making them more active and causing them to deposit more calcium, effectively building bone.

The benefits of strontium’s effects have been impressively demonstrated by clinical trials, which have shown that strontium reduces fracture rates at all sites, including hip and vertebral areas which are the most common fracture areas associated with osteoporosis. Strontium can also reduce the rate of height loss and free patients of back pain.

In Partnership
The mechanisms of Advanced Bone Protection and Strontium are distinct, yet synergistic. Strontium increases bone formation, while MBP reduces the rate at which bone is destroyed. Their actions reduce bone breakdown without reducing the activity of bone building cells. The combination of these two nutrients is therefore a perfect match for effective bone support.

*See references and abstracts below.

Suggested Usage: Take one to two capsules per day on an empty stomach, at least two hours before or after food, calcium or milk but ensure that daily calcium intake is adequate. Calcium, food and milk products significantly reduce strontium absorption if taken at the same sitting.

• Pharmaceutical synthesis (Strontium citrate)
• Bovine Milk (MBP)>

Cautions: Not recommended for children, adolescents, pregnant/nursing women or people with milk allergies. Talk to your health care practitioner before taking if you have kidney disease. Discontinue immediately and permanently if rash occurs and consult a health care practitioner. Do not take if you are taking tetracycline or quinolone antibiotics. Those who have had a hypersensitivity reaction, or have (or are at risk for) DRESS or Stevens Johnson-Syndrome and Venous Thromboembolism (VTE) must not use this product.

Serving Size: 1 capsule
Servings per Container: 60


% DV

Strontium (from citrate)* 340.5mg **
MBP (a specific basic protein fraction derived from milk) 20 mg **

Other Ingredients: None. Capsule: hypromellose.
* Produced through pharmaceutical synthesis.
** Daily Value (% DV) not established.


"Mainichi Hone Kea MBP" is a foods for specified health uses (FOSHU) product. It has been approved to write the next claim, "This product is suitable for those who care about bone health, because it contains MBP that has an effect to increase bone density", on this product. MBP is a complex of protein with a basic isoelectric point in milk protein. It has been shown that MBP promotes bone formation, suppresses bone resorption, increases bone mineral density, and increases bone strength in in vitro and in vivo studies. And, we also examined the effect of MBP in healthy adult women from twenties to fifties. A beverage containing MBP or a placebo beverage without MBP was given to volunteers for six months. The percentage increase of radial bone density was significantly higher in the MBP group than in the placebo group. This result has confirmed that MBP contributes to increased bone density in humans. To sum up, we believe that MAINICHI HONE KEA MBP, which contains MBP that has an effect to increase bone density, contributes to bone health.

Milk basic protein increases bone mineral density and improves bone metabolism in healthy young women.
Osteoporos Int. 2007 Mar;18(3):385-90. Epub 2006 Oct 18.
Uenishi K, Ishida H, Toba Y, Aoe S, Itabashi A, Takada Y.

Effect of milk basic protein on bone metabolism in healthy young women.
INTRODUCTION: Milk has more beneficial effects on bone health than other food sources. Recent in vitro and in vivo studies have shown that milk whey protein, especially its basic protein fraction (milk basic protein, MBP), contains several components capable of promoting bone formation and inhibiting bone resorption. The object of this study was to examine the effect of MBP on the bone mineral density and bone metabolism of healthy young women.
METHODS: Thirty-five healthy young women were randomly assigned to treatment with either placebo or MBP (40 mg per day) for 6 months. The bone mineral density (BMD) of the lumbar vertebrae L2-L4 of each subject was measured by dual-energy X-ray absorptiometry (DXA) at 0 and 6 months of treatment. Serum and urine indexes of bone metabolism were measured at 0, 3 and 6 months. All subjects completed the study in accordance with the protocol.
RESULTS: The mean rate of gain of lumbar BMD in the MBP group (1.57%) was significantly higher than in the placebo group (0.13%, P=0.042). When compared with the placebo group, urinary cross-linked N-telopeptides of type-I collagen (NTx) were significantly decreased, and serum osteocalcin was significantly increased in the MBP group at 6 months.
CONCLUSION: These results suggested that MBP supplementation was effective in increasing BMD in young women and that this increase in BMD may be primarily mediated through the promotion of bone formation and inhibition of bone resorption by MBP supplementation.

Milk basic protein increases alveolar bone formation in rat experimental periodontitis.
J Periodontal Res. 2007 Feb;42(1):85-9.
Seto H, Toba Y, Takada Y, Kawakami H, Ohba H, Hama H, Horibe M, Nagata T.

BACKGROUND AND OBJECTIVE: It is conceivable that the active components extracted from milk whey protein (i.e. milk basic protein, MBP) stimulate bone formation and suppress bone resorption. Periodontitis is characterized by excessive alveolar bone resorption. We examined whether milk basic protein could recover alveolar bone loss in rat experimental periodontitis.
MATERIAL AND METHODS: A nylon ligature was placed around the cervix of molars in 8-wk-old male Fischer rats for 20 d. Then, the ligature was removed and a powder diet containing 0.2 or 1.0% milk basic protein was provided daily for another 45-90 d. On days 45 and 90, the maxillae were extracted and analyzed using microcomputerized tomography (micro-CT), followed by histological analysis.
RESULTS: Micro-CT images showed that alveolar bone resorption was severely induced around the molar by the 20-d ligature procedure. Treatment with high-dose milk basic protein (1.0%) clearly recovered ligature-induced alveolar bone resorption on days 45 and 90, whereas low-dose milk basic protein (0.2%) did not show such a clear effect. Histological examination clarified that the osteoid thickness of alveolar bone was dose dependently increased by milk basic protein treatment for 90 d.
CONCLUSION: These findings suggest that a systemic administration of milk basic protein may be effective for the recovery of alveolar bone loss in periodontitis.

The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in man.
Bull Hosp Joint Dis. 1952 Apr; 13(1): 59-66.
Shorr E, Carter AC.

The results are described of a current investigation of the possible value of Sr as an adjuvant to Ca in the remineralization of the depleted skeleton in a variety of derangements of bone metabolism in man. Sr, in amounts sufficient to achieve significant retention of this element, has been well tolerated over several years of administration and without toxic effects. The retention of Sr is augmented by agents such as Vitamin D, estrogens, and androgens in a similar manner to Ca. When given in equal amounts, Sr is found to have certain distinct advantages over Ca for the remineralization of the skeleton. There is greater retention of Sr; and when the ceiling for Ca retention has been reached, the addition of Sr results in a retention of the latter. Hence, the deposition of Ca plus Sr is greater than the total Ca storage which can be achieved with Ca alone, regardless of Ca intake and auxiliary therapy. This combination should hasten the rate of remineralization of the skeleton as compared with Ca alone, an inference that is supported by the objective and subjective improvement observed under the combined regime. Maximal retention of Sr and Ca is achieved with the assistance of three auxiliary agents-Vitamin D, estrogens and androgens. Finally, the usefulness of Sr as a means of measuring mineral salt turnover in bone is suggested.

The effect of strontium lactate in the treatment of osteoporosis.
Proc Staff Meetings Mayo Clin. 1959; 34(13): 329-34.
McCaslin FE Jr, Janes JM.

A study has been made of the case records of 32 patients treated for osteoporosis with strontium lactate, or strontium lactate with hormones, and then traced for various periods with repeated physical and roentgenographic examinations. Marked subjective improvement was experienced by 84 percent of the patients. Although the mechanism of action of strontium lactate in the treatment of osteoporosis remains to be elucidated, the therapeutic value of the drug appears to be established.

Histomorphomerty of Bone Changes in Stable Strontium Therapy
Trace Subst Env Health. 1985; 19: 193-208.
Marie PJ, Skoryna SC, Pivon RJ Chabot G, Glorieux FH, Stara JF

Previous studies in rats have shown that low dosage of stable Sr2+ added to drinking water stimulates bone formation (7). Low doses of Sr2+ are currently used in treating metastic bone cancer and osteoporosis (17). In the present paper, histomorphometric changes in transiliac bone biopsy material obtained in six patients, before and after 6 months of Stable Strontium Therapy (SST), are reported. All cases had clinically diagnosable osteoporosis. Sr2+ was administered as Sr carbonate, 600-700mg per day. No side effects were observed. Serum Sr:Ca ratio changed from pre SST of 1:1250 (±176) to 1:12 (±0.35) post SST. Bone Sr:Ca ratio changed from 1:1276 (±852) to 1:166 (±74). Mean bone Ca2+ increased slightly but not significantly. Following SST, all histological parameters of bone formation increased, while bone resorption remained unchanged. An increased amount of osteoid tissue was observed, associated with stimulation of bone formation at the tissue level. No significant elevation of trabecular bone volume was found. Clinical observations suggest that the response to SST is better in younger (post-menopausal) cases than in senile osteoporosis. Long-term studies are necessary to determine whether the increase in trabecular calcified bone volume observed in rodents, following low dosage of Sr2+, also occurs in human subjects.

Strontium ranelate reduces the risk of hip fractures in women with postmenopausal osteoporosis.
Osteoporos Int. 2002 Nov;13 (Suppl 3): S14(AbsO14).
Reginster J-Y, Sawicki A, Devogelaer JP, Padrin JM, Kaufma JM, Doyle DV, Fardellone P, Graham J, Felsenberg D, Tulassay Z, Soren-Sen OH, Luisett G, Rizzoli R, Blotman F, Pheneko C, Meunier PJ.

Preclinical and clinical studies have demonstrated that strontium ranelate (S12911) is a bone forming agent with anti-resorptive activity which increases bone mass and bone biomechanical resistance. A dose-ranging clinical study (STRATOS) has determined the 2g-daily dose to be the optimal dose in increasing lumbar BMD.
A randomised double-blind, placebo controlled, phase 3 clinical trial (SOTI study), involving 72 centres in 12 countries, was designed to assess the anti-vertebral fracture efficacy and safety of S12911 (2g/d orally) in women with postmenopausal osteoporosis over a 3 year period. Patients also received daily calcium and vitamin D supplements. The patients (n = 1649) were included in two parallel groups [age: 69.7 (7.3); Lumbar BMD: 0.73 (0.12); mean (SD)], 87.5% of them having at least one prevalent vertebral fracture (2.2 prevalent VF per patient).
A 41% reduction in relative risk (RR) of experiencing a first new vertebral fracture (semi-quantitative assessment) was observed with strontium ranelate throughout the 3 year study compared to placebo, 139 patients with VF versus 222 respectively (RR = 0.59, 95%CI [0.48;0.73], p<0.001) in the intent-to-treat population. These results have also been confirmed when combining both diagnostic methods (semi-quantitative + quantitative) for incident vertebral fracture. Bone specific alkaline phosphatase increased while serum CTX decreased. The lumbar BMD increased in the treated group when compared to the placebo group (+11.4% versus -1.3% respectively, p<0.001). S12911 was well tolerated without any specific adverse event and no deleterious effects were observed on rates of non-vertebral fractures.
We infer that strontium ranelate is a new orally effective and safe treatment of vertebral osteoporosis with a unique mechanism of action.

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
N Engl J Med. 2004 Jan 29;350(5):459-68.
Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.

BACKGROUND: Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug that dissociates bone remodeling by increasing bone formation and decreasing bone resorption, has been shown to reduce the risk of vertebral fractures and to increase bone mineral density.
METHODS: To evaluate the efficacy of strontium ranelate in preventing vertebral fractures in a phase 3 trial, we randomly assigned 1649 postmenopausal women with osteoporosis (low bone mineral density) and at least one vertebral fracture to receive 2 g of oral strontium ranelate per day or placebo for three years. We gave calcium and vitamin D supplements to both groups before and during the study. Vertebral radiographs were obtained annually, and measurements of bone mineral density were performed every six months.
RESULTS: New vertebral fractures occurred in fewer patients in the strontium ranelate group than in the placebo group, with a risk reduction of 49 percent in the first year of treatment and 41 percent during the three-year study period (relative risk, 0.59; 95 percent confidence interval, 0.48 to 0.73). Strontium ranelate increased bone mineral density at month 36 by 14.4 percent at the lumbar spine and 8.3 percent at the femoral neck (P<0.001 for both comparisons). There were no significant differences between the groups in the incidence of serious adverse events.
CONCLUSIONS: Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures.
Mechanisms of action and therapeutic potential of strontium in bone.
Calcif Tissue Int 2001 Sep; 69(3): 121-9.
Marie PJ, Ammann P, Boivin G, Rey C.

The processes of bone resorption and formation are tightly governed by a variety of systemic and local regulatory agents. In addition, minerals and trace elements affect bone formation and resorption through direct or indirect effects on bone cells or bone mineral. Some trace elements closely chemically related to calcium, such as strontium (Sr), have pharmacological effects on bone when present at levels higher than those required for normal cell physiology. Indeed, strontium was found to exert several effects on bone cells. In addition to its antiresorptive activity, strontium was found to have anabolic activity in bone, and this may have significant beneficial effects on bone balance in normal and osteopenic animals. Accordingly, strontium has been thought to have potential interest in the treatment of osteoporosis. This review summarizes the mechanisms of action of strontium on bone cells, the evidence for its beneficial effects on bone mass in vivo, and its potential therapeutic effects in osteopenic disorders.

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.
Osteoporos Int 2002 Dec; 13(12): 925-31.
Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C.

Early postmenopausal women ( n = 160) were randomised to receive placebo or strontium ranelate (SR) 125 mg/day, 500 mg/day or 1 g/day for 2 years (40 participants per group). All participants received calcium 500 mg/day. The primary efficacy parameter was the percent variation in lumbar bone mineral density (BMD), measured using dual-energy X-ray absorptiometry. Secondary efficacy criteria included hip BMD and biochemical markers of bone turnover. At month 24, SR 1 g/day significantly increased lumbar BMD compared with placebo [mean (SD) +5.53% (5.12); p<0.001] for measured values and [mean (SD) +1.41% (5.33%); p<0.05] for values adjusted for bone strontium content. The annual increase for adjusted values was +0.66% compared with -0.5% with placebo, with an overall beneficial effect after 2 years of about 2.4% with SR 1 g/day relative to placebo. There were no other significant between-group differences in adjusted lumbar BMD. Femoral neck and total hip BMD were also significantly increased at month 24 with SR 1 g/day compared with placebo [mean (SD): +2.46% (4.78) and +3.21% (4.68), respectively; both p<0.001)]. SR 1 g/day significantly increased bone alkaline phosphatase at all time points ( p<0.05) compared with baseline and between-group analysis showed a significant increase, compared with placebo, at month 18 ( p = 0.048). No effect on markers of bone resorption was observed. SR was as well tolerated as placebo. The minimum does at which SR is effective in preventing bone loss in early postmenopausal non-osteoporotic women is therefore 1 g/day.

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide medical advice to individuals. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes. Any reproduction in whole or part and in print or electronic form without express permission is strictly forbidden. Permission to reproduce selected material may be granted by contacting AOR Inc.

Copyright © 2005, Advanced Orthomolecular Research


Aoe S, et al. A controlled trial of the effect of milk basic protein (MBP) supplementation on bone metabolism in healthy menopausal women. Osteoprosis International. 2005 Dec;16(12):2123-8. Epub 2005 Aug 31.

Aoe S, et al. Controlled Trial of the Effects of Milk Basic Protein (MBP) Supplementation on Bone Metabolism in Healthy Adult Women. Biosci. Biotechnol. Biochem. Vol.65 pp.913-918. 2001.

Matsuoka Y, et al. Cystatin C in Milk Basic Protein (MBP) and Its Inhibitory Effect on Bone Resorption in Vitro. Biosci. Biotechnol. Biochem. 2002. Vol.66 pp.2531-2536.

Takada Y, et al. Milk Basic Protein Increases Bone Mineral Density and Improves Bone Metabolism In Humans. Nutritional Aspects of Osteoporosis 2nd Ed. (2004); pp. 413-429.

Toba S, et al. Milk Basic Protein Promotes Bone Formation and Suppresses Bone Resorption in Healthy Adult Men. Biosci. Biotechnol. Biochem. Vol.65 pp.1353-1357. 2001

Sips, AJAM et-al. Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility.Br. J Clin Pharmacol. 1996;41:543-549

Sips, AJAM.Absoption kinetics of strontium and calcium in human and experimental animal. Ph.D Thesis. University of Amsterdam. 1994

Skoryna, SC. Effects of oral supplementation with stable strontium. Can Med J. 1981;125:703-712

ATSDR.Toxicological profile for strontium. Atlanta,GA: Agency for toxic substances and disease registry US Dept of Health and Human Services. Public Health Services.2001

Leeuwenkamp,OR et-al. Human pharmacokinetics of orally administered strontium. Calcif. Tissue Int. 1990;47:136-140

Marie,PJ et-al. Effect of low doses of stable strontium on bone metabolism in rats. Mineral Electrolyte Metab. 1985;11:5-13

Shorr, E and Carter, AC. The value of strontium as an adjuvant to calcium in the mineralization of the skeleton in osteoporosis in man. Conference on Metabolic Interactions. Eds. EC Reifenstein Jr.,NY.NY.Pub J Macy Foundation 1950 pp144-154.

McCaslin FE and Janes, HM. The effect of strontium lactate in the treatment of osteoporosis. Proc. Mayo Clinic. 1959;34:329-334

Skoryna,SC and Fuskova, M. In: Skoryna, SC ed. Handbook of stable strontium.NY;Plenum:1985.p593-617

Comar,CL , Wasserman, RH and Nold, NM. Strontium-Calcium discrimination factors in the rat. Proc. Sco. Exp. Biol. Med.1950;92:859-863

Della Rossa et-al. Absorption and retention of ingested strontium and calcium in beagles as a function of age. Nature.1965;205:197-198

Skoryna, SC.Metabolic aspects of the pharmacologic uses of trace elements in human subjects with specific references to stable strontium. Trace Subst. Enviorn Health.1984;18:3-23
Dahl, SG et-al. Incorporation and distribution of strontium in bone. Bone.2001;28:446-453

Storey,E. Strontium “rickets” bone calcium and strontium changes. Austral.Ann. Med. 1961;10:213-222

Matsumoto, A. Effect of strontium chloride on bone resorption induced by prostaglandin E2 in cultured bone. Arch. Toxicol. 1988;62:240-241

Marie,PJ et-al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int.2001;69:121-129

*The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide medical advice to individuals. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

FAQs Q: I noticed that the dosage instructions for Advanced Bone Protection only pertain to women. Can men take it as well? A: Yes. The only reason that the dosage instructions only pertain to women is because the Canadian Ministry of Health (with whom this product is registered) reviewed the human trials for this product and found that the volunteers used in those trials happened to be entirely female. This is in no small part due to the fact that women are more likely to suffer from osteoporosis/osteopenia than men. However, ABP is perfectly safe and effective for men as well.
Q: Is Advanced Bone Protection suitable for me if I am intolerant to milk? A: Yes, Advanced Bone Protection contains a very specific milk protein known as Milk Basic Protein and should not be problematic for you even if you are intolerant to lactose or casein. However, if you've suffered from a severe allergic reaction to milk in the past, Advanced Bone Protection is not suitable for you.
Q: Why should strontium be taken on an empty stomach? A: The presence of food in the stomach reduces the bioavailability of Strontium from about 24% to 19%. Since Strontium is used for the treatment of osteoporosis and is typically used for several years, this can make a big difference vis a vis it's long term efficacy.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Complementary Items for Your Personal Supplement Program:

BioSil Liquid Silicon (Choline-Stabolized Orthosilicic Acid Ch-OSA) 1 fl oz (30 ml) BioSil Liquid Silicon (Choline-Stabolized Orthosilicic Acid Ch-OSA) 1 fl oz (30 ml)
Code: J-BSIL
Price: $25.59
AddTitle: - Natural Factors
Quantity in Basket: none
Advanced Bone Protection - 30 vegi-caps - AOR (08111) Advanced Bone Protection - 30 vegi-caps - AOR (08111)
Price: $23.97
AddTitle: - Advanced Orthomolecular Research
Quantity in Basket: none

Strontium Support II - 341 mg per vegi-cap - 120 vegi-caps - AOR (08204) Strontium Support II - 341 mg per vegi-cap - 120 vegi-caps - AOR (08204)
Code: AOR-SS120
Price: $35.97
AddTitle: - Advanced Orthomolecular Research
Quantity in Basket: none